Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy

Abstract

Tacrolimus could be used in compliant patients with difficult to treat AIH in experienced centers. Its use is safe and can improve liver biochemistry, IgG and reduce steroid requirement. However, due to the lack of immunomodulatory effect, unmet need for effective immune-regulatory therapies still remain for AIH patients.